Crit Care:利尿剂可减少有创机械通气患者的体液平衡

2021-03-12 MedSci原创 MedSci原创

利尿疗法减少了接受机械通气患者的液体积聚,且耐受性良好,安全性良好。

液体超负荷与危重病人的发病率和死亡率增加密切相关。

近日,危重病医学领域权威杂志Critical Care上发表了一篇研究文章,该研究旨在评估利尿剂在有创机械通气患者中纠正体液平衡的有效性和安全性。

该研究为一项多中心、单盲、随机对照研究。患者被随机分为利尿剂组(速尿组)和对照组。如患者在入住ICU后体重增加≥3%、有创机械通气(FiO2≤60%、PEEP≤10cmH2O)、血流动力学稳定,则为液体超负荷。该研究的主要结局为体液平衡,定义为从基础体重到成功拔管的体重变化。该研究的次要结局为利尿剂的安全性。

171名患者随机分组。排除5例患者后,166例患者纳入分析,其中77例为利尿剂组,89例为对照组。利尿剂组的体液平衡为1.4[-2.5至-4.5]kg,对照组为6.4[0.5至11.2]kg (p<0.001)。在多重归算分析中,利尿剂组的体液平衡显著降低(平均差=-4.8 95%CI为-7.3至-2.5,p<0.001)。利尿剂组死亡11例(14%),对照组死亡16例(18%)(p=0.5)。对照组急性肾损伤加重者67例(75.3%),利尿剂组46例(59.7%)(p=0.03)。

在这项多中心随机对照研究中,利尿疗法减少了接受机械通气患者的液体积聚,且耐受性良好,安全性良好

原始出处:

Raphaël Cinotti.et al.Diuretics decrease fluid balance in patients on invasive mechanical ventilation: the randomized-controlled single blind, IRIHS study.Critical Care.2021.https://ccforum.biomedcentral.com/articles/10.1186/s13054-021-03509-5

版权声明:
本网站所有内容来源注明为“梅斯医学”或“MedSci原创”的文字、图片和音视频资料,版权均属于梅斯医学所有。非经授权,任何媒体、网站或个人不得转载,授权转载时须注明来源为“梅斯医学”。其它来源的文章系转载文章,或“梅斯号”自媒体发布的文章,仅系出于传递更多信息之目的,本站仅负责审核内容合规,其内容不代表本站立场,本站不负责内容的准确性和版权。如果存在侵权、或不希望被转载的媒体或个人可与我们联系,我们将立即进行删除处理。
在此留言
评论区 (4)
#插入话题
  1. [GetPortalCommentsPageByObjectIdResponse(id=1271964, encodeId=97f512e1964fe, content=<a href='/topic/show?id=573332291bd' target=_blank style='color:#2F92EE;'>#利尿剂#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=53, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=32291, encryptionId=573332291bd, topicName=利尿剂)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=ca89104, createdName=huperzia, createdTime=Sun Mar 14 13:22:09 CST 2021, time=2021-03-14, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=947969, encodeId=c71e94e96923, content=继续来学习了, beContent=null, objectType=article, channel=null, level=null, likeNumber=93, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://img.medsci.cn/20200627/83a502bff6c14b759a7d0863b4068e7b/32ad40676056418ea58a94afac9c5b81.jpg, createdBy=6f475314305, createdName=水-晶, createdTime=Sat Mar 13 23:41:32 CST 2021, time=2021-03-13, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=947898, encodeId=1c4394e89899, content=好, beContent=null, objectType=article, channel=null, level=null, likeNumber=88, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=25db5468686, createdName=ms9000000233597628, createdTime=Sat Mar 13 17:00:25 CST 2021, time=2021-03-13, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=947808, encodeId=7b9394e808c2, content=学习了, beContent=null, objectType=article, channel=null, level=null, likeNumber=73, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=http://cdnapi.center.medsci.cn/medsci/head/2019/04/08/cd88d0de650f7d6e5a75267c5d42457a.jpg, createdBy=67cb1548356, createdName=ms9000001731190948, createdTime=Sat Mar 13 09:18:08 CST 2021, time=2021-03-13, status=1, ipAttribution=)]
  2. [GetPortalCommentsPageByObjectIdResponse(id=1271964, encodeId=97f512e1964fe, content=<a href='/topic/show?id=573332291bd' target=_blank style='color:#2F92EE;'>#利尿剂#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=53, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=32291, encryptionId=573332291bd, topicName=利尿剂)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=ca89104, createdName=huperzia, createdTime=Sun Mar 14 13:22:09 CST 2021, time=2021-03-14, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=947969, encodeId=c71e94e96923, content=继续来学习了, beContent=null, objectType=article, channel=null, level=null, likeNumber=93, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://img.medsci.cn/20200627/83a502bff6c14b759a7d0863b4068e7b/32ad40676056418ea58a94afac9c5b81.jpg, createdBy=6f475314305, createdName=水-晶, createdTime=Sat Mar 13 23:41:32 CST 2021, time=2021-03-13, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=947898, encodeId=1c4394e89899, content=好, beContent=null, objectType=article, channel=null, level=null, likeNumber=88, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=25db5468686, createdName=ms9000000233597628, createdTime=Sat Mar 13 17:00:25 CST 2021, time=2021-03-13, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=947808, encodeId=7b9394e808c2, content=学习了, beContent=null, objectType=article, channel=null, level=null, likeNumber=73, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=http://cdnapi.center.medsci.cn/medsci/head/2019/04/08/cd88d0de650f7d6e5a75267c5d42457a.jpg, createdBy=67cb1548356, createdName=ms9000001731190948, createdTime=Sat Mar 13 09:18:08 CST 2021, time=2021-03-13, status=1, ipAttribution=)]
    2021-03-13 水-晶

    继续来学习了

    0

  3. [GetPortalCommentsPageByObjectIdResponse(id=1271964, encodeId=97f512e1964fe, content=<a href='/topic/show?id=573332291bd' target=_blank style='color:#2F92EE;'>#利尿剂#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=53, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=32291, encryptionId=573332291bd, topicName=利尿剂)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=ca89104, createdName=huperzia, createdTime=Sun Mar 14 13:22:09 CST 2021, time=2021-03-14, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=947969, encodeId=c71e94e96923, content=继续来学习了, beContent=null, objectType=article, channel=null, level=null, likeNumber=93, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://img.medsci.cn/20200627/83a502bff6c14b759a7d0863b4068e7b/32ad40676056418ea58a94afac9c5b81.jpg, createdBy=6f475314305, createdName=水-晶, createdTime=Sat Mar 13 23:41:32 CST 2021, time=2021-03-13, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=947898, encodeId=1c4394e89899, content=好, beContent=null, objectType=article, channel=null, level=null, likeNumber=88, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=25db5468686, createdName=ms9000000233597628, createdTime=Sat Mar 13 17:00:25 CST 2021, time=2021-03-13, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=947808, encodeId=7b9394e808c2, content=学习了, beContent=null, objectType=article, channel=null, level=null, likeNumber=73, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=http://cdnapi.center.medsci.cn/medsci/head/2019/04/08/cd88d0de650f7d6e5a75267c5d42457a.jpg, createdBy=67cb1548356, createdName=ms9000001731190948, createdTime=Sat Mar 13 09:18:08 CST 2021, time=2021-03-13, status=1, ipAttribution=)]
    2021-03-13 ms9000000233597628

    0

  4. [GetPortalCommentsPageByObjectIdResponse(id=1271964, encodeId=97f512e1964fe, content=<a href='/topic/show?id=573332291bd' target=_blank style='color:#2F92EE;'>#利尿剂#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=53, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=32291, encryptionId=573332291bd, topicName=利尿剂)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=ca89104, createdName=huperzia, createdTime=Sun Mar 14 13:22:09 CST 2021, time=2021-03-14, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=947969, encodeId=c71e94e96923, content=继续来学习了, beContent=null, objectType=article, channel=null, level=null, likeNumber=93, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://img.medsci.cn/20200627/83a502bff6c14b759a7d0863b4068e7b/32ad40676056418ea58a94afac9c5b81.jpg, createdBy=6f475314305, createdName=水-晶, createdTime=Sat Mar 13 23:41:32 CST 2021, time=2021-03-13, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=947898, encodeId=1c4394e89899, content=好, beContent=null, objectType=article, channel=null, level=null, likeNumber=88, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=25db5468686, createdName=ms9000000233597628, createdTime=Sat Mar 13 17:00:25 CST 2021, time=2021-03-13, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=947808, encodeId=7b9394e808c2, content=学习了, beContent=null, objectType=article, channel=null, level=null, likeNumber=73, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=http://cdnapi.center.medsci.cn/medsci/head/2019/04/08/cd88d0de650f7d6e5a75267c5d42457a.jpg, createdBy=67cb1548356, createdName=ms9000001731190948, createdTime=Sat Mar 13 09:18:08 CST 2021, time=2021-03-13, status=1, ipAttribution=)]
    2021-03-13 ms9000001731190948

    学习了

    0

相关资讯

JAHA:门诊利尿剂强化治疗会增加心衰患者死亡风险

失代偿性心力衰竭(HF)住院后死亡率增加,在此期间利尿剂通常会加重,目前尚不清楚在门诊强化利尿剂治疗心力衰竭后风险是如何影响的。

J Gastroenterology:存在腹水的肝硬化患者使用利尿剂对肌肉痉挛的影响

据报道,存在腹水的肝硬化患者使用利尿剂与肌肉痉挛有关。但是,临床证据有限。这项研究旨在确定肌肉痉挛是否是利尿药引起的并发症,以及腹水是否与肌肉痉挛有关。

Am J Med:CA125指导下的利尿策略能显著改善急性心衰和肾功能障碍患者短期的肾功能

急性心力衰竭和肾功能障碍患者的最佳利尿治疗策略仍不明确。血浆碳水化合物抗原125(CA125)是液体超负荷的代用指标,也是指导利尿治疗的潜在有价值的工具。

Circulation:依帕列净治疗心力衰竭:利尿和心肾效应

钠-葡萄糖共转运体-2抑制剂可改善心力衰竭(心衰)的相关预后。然而,其机制尚不清楚,但利尿剂的特性可能起到一定作用。传统的利尿剂(如速尿)可诱导大量神经激素激活,导致经常出现有限的血管内容量改善。然而

Hypertension:慢性肾脏病患者血压变异性和利尿剂与心血管事件的关系

在慢性肾病患者中,BPV与心血管事件和死亡相关,但与终末期肾脏疾病无关,BPV五分位数较高的利尿剂治疗组中其与心血管事件的相关性有所减弱。未来的研究应调查其他降压药是否会改变这些风险。

Circulation:基础利尿剂应用对达格列净治疗心衰时的疗效的影响

研究表明,钠葡萄糖共转运体2抑制剂达格列净降低了射血分数降低的心衰患者的心衰恶化和死亡风险。本研究拟评估达格列净与基础利尿剂治疗和达格列净对利尿剂剂量的影响。